Frontier Wealth Management’s AbbVie ABBV Stock Holding History

Frontier Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$8M	Buy	52,199 +8,734	+20%	+$1.33M	0.58%	44
2022 Q1	$7.27M	Sell	43,465 -14,920	-26%	-$2.17M	0.09%	43
2021 Q4	$7.91M	Buy	58,385 +1,304	+2%	+$154K	0.52%	40
2021 Q3	$6.16M	Buy	57,081 +1,602	+3%	+$183K	0.43%	50
2021 Q2	$6.25M	Buy	55,479 +3,898	+8%	+$439K	0.44%	45
2021 Q1	$5.58M	Sell	51,581 -299	-0.6%	-$32K	0.43%	46
2020 Q4	$5.56M	Buy	51,880 +8,991	+21%	+$864K	0.46%	46
2020 Q3	$3.76M	Buy	42,889 +1,696	+4%	+$160K	0.34%	55
2020 Q2	$4.04M	Buy	41,193 +5,348	+15%	+$471K	0.37%	51
2020 Q1	$2.73M	Buy	35,845 +27,514	+330%	+$2.34M	0.45%	62
2019 Q4	$738K	Sell	8,331 -11,736	-58%	-$974K	0.12%	136
2019 Q3	$1.52M	Sell	20,067 -432	-2%	-$29.6K	0.22%	95
2019 Q2	$1.49M	Buy	20,499 +157	+0.8%	+$12.3K	0.22%	94
2019 Q1	$1.64M	Sell	20,342 -540	-3%	-$44.2K	0.22%	97
2018 Q4	$1.93M	Sell	20,882 -2,263	-10%	-$199K	0.29%	82
2018 Q3	$2.19M	Buy	23,145 +797	+4%	+$75.6K	0.21%	78
2018 Q2	$2.07M	Buy	22,348 +663	+3%	+$64.8K	0.3%	81
2018 Q1	$2.05M	Buy	21,685 +2,871	+15%	+$315K	0.29%	86
2017 Q4	$1.82M	Sell	18,814 -2,819	-13%	-$266K	0.29%	82
2017 Q3	$1.92M	Buy	21,633 +501	+2%	+$38.1K	0.28%	93
2017 Q2	$1.53M	Sell	21,132 -18	-0.1%	-$1.21K	0.23%	104
2017 Q1	$1.38M	Sell	21,150 -3,424	-14%	-$215K	0.21%	122
2016 Q4	$1.54M	Buy	24,574 +889	+4%	+$54.3K	0.25%	109
2016 Q3	$1.49M	Buy	23,685 +1,505	+7%	+$97.4K	0.23%	104
2016 Q2	$1.37M	Buy	22,180 +658	+3%	+$40.1K	0.22%	110
2016 Q1	$1.23M	Buy	21,522 +3,346	+18%	+$186K	0.1%	115
2015 Q4	$1.08M	Buy	18,176 +826	+5%	+$47.6K	0.17%	124
2015 Q3	$944K	Buy	17,350 +7,719	+80%	+$502K	0.15%	138
2015 Q2	$647K	Buy	+9,631	New	+$629K	0.1%	173

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Frontier Wealth Management's ABBV Position: Q2 2022 in Review

Frontier Wealth Management increased its AbbVie (ABBV) stake by 20% in Q2 2022, buying an estimated $1.33M and bringing the position to 52,199 shares worth $8M. The position accounts for 0.58% of the portfolio, ranked #44.

Frontier Wealth Management first reported a position in ABBV in Q2 2015 and has held it in 29 quarters since. 3,006 funds tracked by Wall St. Rank hold ABBV as of Q2 2022.

Frontier Wealth Management held 52,199 shares of AbbVie worth $8M as of Q2 2022.
Frontier Wealth Management bought 8,734 AbbVie shares in Q2 2022, an estimated $1.33M.
AbbVie made up 0.58% of Frontier Wealth Management's portfolio in Q2 2022, its #44 holding.
Frontier Wealth Management first reported a position in AbbVie in Q2 2015 and has held it in 29 quarters since.
3,006 funds tracked by Wall St. Rank held AbbVie as of Q2 2022.

Based on Frontier Wealth Management's 13F filing for Q2 2022, filed 12 Aug 2022.